US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

Alamar Biosciences (ALMR): Bio-Platform Company Scales, Draws Heavy IPO Interest

Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

IPOs and Secondary Offerings

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul>
<li>Alamar Biosciences IPO priced at $17.00 after being upsized; opened up 32.9% reflecting strong institutional demand.</li>
<li>Deal was ~12x oversubscribed with highly concentrated allocations; top 25 accounts received ~80% of shares.</li>
<li>Revenue-Generating proteomics platform scaling rapidly, with $74.2M revenue and expanding margins driving investor interest.</li>
</ul>


Alamar Biosciences IPO priced at $17.00 after being upsized; opened up 32.9% reflecting strong institutional demand.
Deal was ~12x oversubscribed with highly concentrated allocations; top 25 accounts received ~80% of shares.
Revenue-Generating proteomics platform scaling rapidly, with $74.2M revenue and expanding margins driving investor interest.


알라마르 바이오사이언스(ALMR): 희소성과 성장 잠재력이 단백질체학 플랫폼의 강력한 첫날 상승세를 이끌었습니다.